On This Day in Health: June 4, 2021
On June 4, 2021, the U.S. Food and Drug Administration approved Wegovy, Novo Nordisk's once-weekly semaglutide injection, for chronic weight management in certain adults. The decision by the agency in Silver Spring, Maryland, covered adults with obesity, or overweight accompanied by at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. It brought a new use of semaglutide into U.S. medical practice: the medicine was already associated with treatment of type 2 diabetes, but this approval involved a different indication and dose. The milestone concerned ongoing management of a chronic condition, rather than a promise of rapid or permanent weight loss for everyone.
Semaglutide belongs to a class of medicines that act on the receptor for glucagon-like peptide-1, usually shortened to GLP-1. For weight management, its effects on appetite and food intake were central to the treatment's rationale. The approved program used gradual dose increases to reach the maintenance dose studied for Wegovy. That made the product more than a new brand attached to an existing diabetes treatment: the application addressed a specified population, regimen and set of outcomes. The original adult eligibility criteria used body mass index, with a threshold of thirty for obesity or twenty-seven for overweight when accompanied by a condition such as high blood pressure or type 2 diabetes.
Clinical studies evaluated the medicine together with changes in eating and physical activity, comparing the results with placebo plus those same accompanying measures. A major trial followed adults without diabetes for sixty-eight weeks and found substantially greater average weight loss in the semaglutide group. The result was an average across participants, not a forecast for any one person. Other studies examined different populations and aspects of treatment. The approval also came with safety information: gastrointestinal reactions were common, and the labeling included a boxed warning about thyroid C-cell tumors based on findings in rodents. That warning did not establish the same effect in people, but it shaped restrictions and the information provided with the medicine.
The June decision enlarged the range of medical approaches available for obesity while leaving important practical questions outside the approval itself. A regulatory authorization does not determine whether an individual can obtain or afford a prescription, tolerate treatment or maintain a particular result. Nor should later approvals involving semaglutide be read back into the original 2021 indication. The historical event was the authorization of Wegovy for chronic weight management in a defined adult population. Its broader significance was the application of an established hormonal pathway to an area of care marked by substantial unmet need and stigma. The anniversary provides a way to explain that change through the evidence reviewed, the population covered and the limits of what approval alone could accomplish.
The original approval covered chronic weight management in certain adults with obesity or overweight and a weight-related condition.
Semaglutide acts on the GLP-1 receptor; the weight-management application used a specified regimen and gradual dose escalation.
The clinical program compared semaglutide with placebo alongside dietary and physical-activity measures.
Average trial results did not guarantee an individual's response, and the original labeling included significant safety warnings.
The decision extended semaglutide's use beyond its earlier role in diabetes care.
June 4 marks the original adult weight-management approval, distinct from later changes to the product's indications.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.